Clovis Oncology, Inc.
DelistedCIK 1466301fmd_12XBJ6R7XR7JEYPMG1PPYJTR3NManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Sep 30, 2022, 48 periods
| Line item | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 14 | 0 | 0 | 56 | 95 | 143 | 165 | 149 |
| Cost of revenue | – | – | 0 | 0 | 0 | – | – | – | – | – |
| Gross profit | – | – | 14 | 0 | 0 | – | – | – | – | – |
| Research and development | 59 | 67 | 138 | 269 | 251 | 142 | 231 | 283 | 258 | 187 |
| Selling, general and administrative | – | – | 21 | 31 | 41 | 139 | 176 | 183 | 164 | 128 |
| Total operating expenses | 74 | 84 | 172 | 377 | 373 | 293 | 429 | 520 | 467 | – |
| Operating income | (74) | (84) | (158) | (377) | (373) | (238) | (334) | (377) | (302) | (226) |
| Interest expense | – | – | 3 | 8 | 8 | 10 | 13 | 19 | 31 | 34 |
| Other non-operating income (expense) | (0) | (1) | 1 | (5) | (8) | (112) | (34) | (22) | (68) | (39) |
| Income before taxes | (74) | (84) | (158) | (382) | (381) | (350) | (367) | (399) | (370) | (265) |
| Income tax expense | (0) | 0 | 2 | (29) | (32) | (4) | 1 | 2 | (1) | (0) |
| Net income from continuing operations | (74) | (85) | (160) | (353) | (349) | (346) | (368) | (400) | (369) | (265) |
| Net income | (74) | (85) | (160) | (353) | (349) | (346) | (368) | (400) | (369) | (265) |